Meatable NV raises US$10m in seed fundingMeatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m. more ➔
Big Pharma is cost driver of GAVI Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine more ➔
ImCheck Therapeutics SAS raises €48mT cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells. more ➔
Pierre Fabre amends license agreement with...Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib). more ➔
European circular bioeconomy fund near clo...The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund. more ➔
Researchers find new indication for cancer...French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma. more ➔
Research team improves safety of LGMD2A ge...Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer. more ➔
€7.34m for cancer vaccine developer Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes. more ➔
GeNeuro and Karolinska Institute collabora...Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC. more ➔
Tecentriq-Avastin combo hits endpoint in l...Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patien … more ➔
